A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant

被引：0
|
作者：
Qu, J. [1 ]
Liu, L. [2 ]
Heng, J. [2 ]
Zhou, C. [2 ]
Xiong, Y. [2 ]
Jiang, W. [2 ]
Yang, N. [2 ]
机构：
[1] Hunan Prov Canc Hosp, Dept Lung Canc & Gastroenterol, Changsha, Hunan, Peoples R China
[2] Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [31] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    LABORATORY INVESTIGATION, 2010, 90 : 397A - 397A
  • [32] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    MODERN PATHOLOGY, 2010, 23 : 397A - 397A
  • [33] Gold nanorod immunoassay to quantify C-Met expression in NSCLC patients selected for anti-EGFR therapy
    Caldwell, Chuck
    Kannan, Raghuraman
    Arthur, Gerald
    Shin, Dmitry
    Ersoy, Ilker
    Hammer, Richard
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S18 - S18
  • [34] A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy
    Lim, S. M.
    Kim, D-W.
    Jung, J. E.
    Lee, G.
    Ryou, J-H.
    Kang, S-U.
    Lee, Y-H.
    Shin, H-J.
    Yum, S. Y.
    Yim, E.
    Lee, S-Y.
    Ahn, J. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1035 - S1035
  • [35] PDX from the naive NSCLC patients containing activating EGFR mutations are resistant to erlotinib but sensitive to c-met inhibitor
    Yang, Mengmeng
    Deng, Jiangyun
    Song, Xiaoming
    Cai, Jie
    Chen, Taiping
    Chen, Yiyou
    Li, Henry Q. X.
    CANCER RESEARCH, 2012, 72
  • [36] Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
    Urbanska, Edyta M.
    Grauslund, Morten
    Koffeldt, Peter R.
    Truelsen, Sarah L. B.
    Loefgren, Johan O.
    Costa, Junia C.
    Melchior, Linea C.
    Sorensen, Jens B.
    Santoni-Rugiu, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [37] Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study
    Shi, Meiqi
    Chen, Ping
    Cui, Bin
    Yao, Yuanhu
    Wang, Juanyi
    Zhou, Tong
    Wang, Li
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [38] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [39] A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naive Patients with EGFR Mutation-Positive NSCLC: Final Analysis
    Wu, Y.
    Tu, H.
    Feng, J.
    Shi, M.
    Zhao, J.
    Wang, Y.
    Chang, J.
    Wang, J.
    Cheng, Y.
    Zhu, J.
    Tan, E.
    Zhang, Y.
    Lee, V.
    Yang, C.
    Su, W.
    Lam, D. C.
    Srinivasa, B.
    Rajappa, S.
    Ho, C.
    Lam, K. C.
    Hu, Y.
    Bondarde, S. A.
    Liu, X.
    Pang, K.
    Tian, Y.
    Cseh, A.
    Huang, D. C.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S679 - S680
  • [40] Long Progression Free Survival and Overall Survival in Advanced NSCLC Patients with EGFR Mutation and Complete Response with TKI Treatment
    Macedo-Perez, O.
    Lyra-Gonzalez, I.
    Marroquin-Flores, D.
    Cruz-Rico, G.
    Ramirez-Tirado, L.
    Valdez-Rojas, L.
    Tabares-Nanez, A.
    Gonzales-Nogales, J.
    Arrieta, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2087 - S2087
12345